Fig. 6
From: Multi-pathway targeted therapy of MASH-HCC using miR-22
The early intervention with miR-22 effectively treats MASH-HCC in WD- or HFD- induced MASH background. A Study design for miR-22 early intervention in MASH/HCC. 3-week-old male mice were fed a Western Diet (WD) or high-fat diet (HFD) for 3 months, followed by hydrodynamic injection of Myr-AKT1 and NRasV12 (AKT/RAS) with Sleeping Beauty transposase. 1 week prior to oncogene delivery, AAV8-miR-22 or AAV8 blank control (5 × 1012 GC/kg) was administered intravenously. Mice were maintained on a WD or HFD during the entire experiment. B liver-to-body weight (L/B) ratio, C representative liver morphology, H&E, and Sirus red-stained liver sections. Data represent mean ± SD (n = 5–6/group). p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001 by one-way ANOVA